Modulation of Small Intestinal Microbial Composition and Activity,Systemic Immune Adaptation and Blood Transcriptional Changes Induced by 2-wks Consumption With 2 Fermented Milk Products;a Randomized,Exploratory,Cross-over,Double Blind,Controlled Study in Ileostomy Patients

Maastricht University Medical Center1 site in 1 country16 target enrollmentSeptember 2016

ConditionsIleostomy - Stoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Ileostomy - Stoma
Sponsor: Maastricht University Medical Center
Enrollment: 16
Locations: 1
Primary Endpoint: Temporal microbial composition and activity in the small intestine in ileal effluent
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To determine the small intestinal microbiota response in humans to dietary interventions for two consecutive weeks, and to relate this to parameters of intestinal barrier function and immune and metabolic responses in blood, as functional outcome parameters of host physiology

Registry

clinicaltrials.gov

Start Date

September 2016

End Date

November 11, 2017

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Maastricht University Medical Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•• Ileostomy installed at least 3 years prior to participation
•Free of any complications originating from the colectomy procedure for at least 1 yr prior to participation, with the exception of possible skin irritation at the location of the stoma
•BMI from 18 till 28 kg/m2
•Age from 18 till 70 years
•Available for entire study protocol.
•For female: If of child bearing potential, female subjects must be using or complying with methods of contraception (such as oral birth control pills, intra-uterine device, double barrier methods (like condoms and spermicide, etc.)

Exclusion Criteria

•• History of cardiovascular, respiratory, urogenital, hepatic, haematological / immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, laboratory assessments which might limit participation in or completion of the study protocol, and/or major surgery with the exception of total colectomy, hysterectomy and/or appendectomy.
•Subject with known lactose intolerance or with known or suspected allergy or hypersensitivity to any component of the study product(s) (milk protein for example) + sucrose + rhamnose
•Severe gastrointestinal symptoms. In case of mild gastrointestinal symptoms, the principal investigator and the medically responsible MD will judge eligibility to participate.
•Removal of more than 15 cm of the ileum during or at any moment after the colectomy procedure
•Abdominal surgery interfering with gastrointestinal function, upon judgment of the principal investigator and the medically responsible MD
•Use of medication, including proton pump inhibitors, non-steroidal anti-inflammatory drugs interfering with endpoints (but except oral contraceptives), within 14 days prior to and during participation.
•Consumption of any probiotic or prebiotic supplements or pre- and probiotics containing food products, investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principal investigator), in the 4 weeks prior to the study and during study participation (E4 PreProbiotics).
•Use of antibiotics in the 4 weeks prior to the start of study and during study participation
•Prohibited use of pro-, pre- or synbiotics during study period and three months prior to start of study. A list with forbidden products will be provided'
•History of any side effects towards intake of pro- or prebiotic supplements of any kind.

Outcomes

Primary Outcomes

Temporal microbial composition and activity in the small intestine in ileal effluent

Time Frame: 2 weeks intervention

The microbiome activity will be determined as a function of the diet by double strand cDNA production and random sequencing of mRNA enriched fractions of total effluent RNA obtained from the effluent samples at the start and end of each intervention period.

Secondary Outcomes

Peripheral blood metabolome profiles(2 weeks intervention)
Number of participants with Gastrointestinal symptoms by Visual Analogue Scales(2 weeks intervention)
Small intestinal permeability by a multi sugar test (urinary recovery of test sugars)(2 weeks intervention)
Gene transcription response in blood by transcriptome patterns.(2 weeks intervention)
The level of whole blood immune responsiveness to a panel of standardized stimuli ex vivo(2 weeks intervention)
Short chain fatty acid profiles in ileal effluent(2 weeks intervention)
Occurrence and severity of treatment related adverse events(2 weeks intervention)
The levels of a panel of peripheral blood biomarkers related to immune, metabolic and hormonal status(2 weeks intervention)
Morning urine metabolome profiles(2 weeks intervention)
The relative survival of bacterial strains (colony forming unit enumeration on semi-selective culture plates)(2 weeks intervention)